 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular TherapeutixTM, Inc. Nasdaq: OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of 21.50 per share for gross proceeds of approximately 80.1 million, before deducting underwriting discounts and commissions and other of 